This article summarized the latest R&D progress of Dicloxacillin sodium, the Mechanism of Action for Dicloxacillin sodium, and the drug target R&D trends for Dicloxacillin sodium.

BRD4 inhibitors target BRD4 for inhibition, which hold tremendous value in anti-cancer and anti-inflammatory sectors, as well as many other fields.

SpliSense declared the successful completion of a Phase 1 clinical trial for SPL84.

This article summarized the latest R&D progress of Cinacalcet hydrochloride, the Mechanism of Action for Cinacalcet hydrochloride, and the drug target R&D trends for Cinacalcet hydrochloride.

Verismo Therapeutics, a clinical-stage company specializing in CAR-T therapies, has initiated the dosing of the first patient in their STAR-101 clinical trial.

This article summarized the latest R&D progress of Vardenafil hydrochloride, the Mechanism of Action for Vardenafil hydrochloride, and the drug target R&D trends for Vardenafil hydrochloride.

BET (Bromodomain and Extra-Terminal) proteins play a crucial role in the regulation of gene expression in the human body.

Viking Therapeutics, Inc. has recently commenced a Phase 2 clinical evaluation of VK2735.

This article summarized the latest R&D progress of Valrubicin, the Mechanism of Action for Valrubicin, and the drug target R&D trends for Valrubicin.

Atamyo Therapeutics proclaimed that the FDA has given the green light for its ATA-100 IND application to advance into a Phase 1b/2b clinical study.

Bcl-2 inhibitors can be used alone to kill cancer cells or can be used in combination with other drugs to increase the sensitivity of cancer cells to drugs.

VBI Vaccines Inc. publicized that its strategic HBV collaborator, Brii Biosciences announced preliminary group-level unmasked 36-week data from a mid-term examination of a randomly assigned, placebo-controlled, and double-concealed Phase 2 investigation of BRII-179 (VBI-2601).